Quarterly ResultMay 20, 2026, 04:07 PM
20/20 BioLabs Secures $5.0M Private Placement; Q1 Revenue $0.4M
AI Summary
20/20 BioLabs reported its first quarter 2026 financial and operational results, highlighting a $5.0 million private placement that boosted cash to $4.2 million. While Q1 2026 revenue declined to $0.4 million from $0.6 million year-over-year, the company anticipates significant revenue growth from state-funded firefighter cancer screening programs beginning in Q2 2026. Strategic wins include a distribution agreement with Evexia Diagnostics, a CKD license with ROKIT Healthcare, and the commercial launch of OneTest for Longevity.
Key Highlights
- 20/20 BioLabs completed a $5.0 million private placement on February 19, 2026.
- Cash and cash equivalents totaled $4.2 million as of March 31, 2026, up from $1.0 million on December 31, 2025.
- Revenue for Q1 2026 was $0.4 million, down from $0.6 million in Q1 2025.
- Net loss for Q1 2026 was $2.2 million, compared to $0.8 million in Q1 2025.
- Deferred revenue increased to $0.5 million as of March 31, 2026, from $0.4 million.
- Gross margin was 17.8% in Q1 2026, down from 29.9% in the prior year period.
- Total operating expenses increased to $1.5 million in Q1 2026 from $0.9 million in Q1 2025.
- Company expects meaningful revenue growth from state-funded firefighter cancer screening programs starting Q2 2026.
Price Impact
More from AIDX